Influence of demethylation on regulatory T and Th17 cells in myelodysplastic syndrome

Jia,Xinyan; Yang,Wenzhong; Zhou,Xiaohui; Han,Lu; Shi,Jumei

doi:10.3892/ol.2019.11114

Influence of demethylation on regulatory T and Th17 cells in myelodysplastic syndrome

Authors:
- Xinyan Jia
- Wenzhong Yang
- Xiaohui Zhou
- Lu Han
- Jumei Shi
View Affiliations

Affiliations: Department of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, P.R. China, Department of Hematology, Shanghai Tenth People's Hospital, Tongji University Cancer Center, Tongji University School of Medicine, Shanghai 200072, P.R. China
Published online on: November 19, 2019 https://doi.org/10.3892/ol.2019.11114
Pages: 442-448
Copyright: © Jia et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Myelodysplastic syndrome (MDS) represents a heterogeneous hematopoietic disorder in which mature blood cells are derived from an abnormal multipotent progenitor cell. The current therapy for MDS involves repeated cycles of DNA methyltransferase (DNMT) inhibitors, particularly the demethylation drug 5‑azacytidine (5‑azaC) which has been shown to increase the survival of patients with high‑risk MDS. The mechanisms behind the therapeutic effects of 5‑azaC are not yet clear. In this study the effect of 5‑azaC on the development of regulatory T cells (Tregs) and T‑helper 17 (Th17) cells was investigated. The numbers of CD4+ T‑cell subsets in 30 patients with intermediate‑2/high‑risk MDS were serially assessed at diagnosis and following 5‑azaC treatment. The number of FoxP3+ Tregs was significantly higher after 3 months of therapy. However, there was no statistical difference in the number of Th17 cells following treatment. In vitro, 5‑azaC enhanced the overall proportion of Tregs, but not Th17, in CD4+ T cells from patients with MDS. Addition of 5‑azaC reduced the proliferative capacity of Tregs, suggesting that the increase in Tregs was due to conversion of conventional CD25‑ cells, rather than proliferation of CD25+FoxP3+ cells. The FoxP3 expression in 5‑azaC‑treated T effectors was also increased. Interestingly, while Tbet and RORγT mRNA transcription had no obvious changes, due to the demethylation of the FoxP3 promoter, these findings are important in associating the induction of DNA hypomethylation and the clinical response to 5‑azaC.

View Figures

View References

1	Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, et al International Vidaza High-Risk MDS Survival Study Group, : Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol. 10:223–232. 2009. View Article : Google Scholar : PubMed/NCBI
2	Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, et al: Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 28:562–569. 2010. View Article : Google Scholar : PubMed/NCBI
3	Pinto A and Zagonel V: 5-Aza-2-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: Past, present and future trends. Leukemia. 7 (Suppl 1):51–60. 1993.PubMed/NCBI
4	Garcia-Manero G and Fenaux P: Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol. 29:516–523. 2011. View Article : Google Scholar : PubMed/NCBI
5	Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G, Vyas P, Cavenagh J, Stankovic T, Moss P, et al: Induction of a CD8⁺ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood. 116:1908–1918. 2010. View Article : Google Scholar : PubMed/NCBI
6	Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi SH, Yang AS, Aucott T, Dauses T, Odchimar-Reissig R, et al: Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood. 114:2764–2773. 2009. View Article : Google Scholar : PubMed/NCBI
7	Aggarwal S, van de Loosdrecht AA, Alhan C, Ossenkoppele GJ, Westers TM and Bontkes HJ: Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: Implications for immunotherapy. Br J Haematol. 153:568–581. 2011. View Article : Google Scholar : PubMed/NCBI
8	Sánchez-Abarca LI, Gutierrez-Cosio S, Santamaría C, Caballero-Velazquez T, Blanco B, Herrero-Sánchez C, García JL, Carrancio S, Hernández-Campo P, González FJ, et al: Immunomodulatory effect of 5-azacytidine (5-azaC): Potential role in the transplantation setting. Blood. 115:107–121. 2010. View Article : Google Scholar : PubMed/NCBI
9	Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E, Piwnica-Worms DR and DiPersio JF: In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood. 116:129–139. 2010. View Article : Google Scholar : PubMed/NCBI
10	Kordasti SY, Afzali B, Lim Z, Ingram W, Hayden J, Barber L, Matthews K, Chelliah R, Guinn B, Lombardi G, et al: IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol. 145:64–72. 2009. View Article : Google Scholar : PubMed/NCBI
11	Kordasti SY, Ingram W, Hayden J, Darling D, Barber L, Afzali B, Lombardi G, Wlodarski MW, Maciejewski JP, Farzaneh F, et al: CD4⁺CD25^high Foxp3⁺ regulatory T cells in myelodysplastic syndrome (MDS). Blood. 110:847–850. 2007. View Article : Google Scholar : PubMed/NCBI
12	Polansky JK, Kretschmer K, Freyer J, Floess S, Garbe A, Baron U, Olek S, Hamann A, von Boehmer H and Huehn J: DNA methylation controls Foxp3 gene expression. Eur J Immunol. 38:1654–1663. 2008. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Lal G, Zhang N, van der Touw W, Ding Y, Ju W, Bottinger EP, Reid SP, Levy DE and Bromberg JS: Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol. 182:259–273. 2009. View Article : Google Scholar : PubMed/NCBI
15	Nagar M, Vernitsky H, Cohen Y, Dominissini D, Berkun Y, Rechavi G, Amariglio N and Goldstein I: Epigenetic inheritance of DNA methylation limits activation-induced expression of FOXP3 in conventional human CD25⁻CD4⁺ T cells. Int Immunol. 20:1041–1055. 2008. View Article : Google Scholar : PubMed/NCBI
16	Costantini B, Kordasti SY, Kulasekararaj AG, Jiang J, Seidl T, Abellan PP, Mohamedali A, Thomas NS, Farzaneh F and Mufti GJ: The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome. Haematologica. 98:1196–1205. 2013. View Article : Google Scholar : PubMed/NCBI
17	Whiteside TL: Regulatory T cell subsets in human cancer: Are they regulating for or against tumor progression? Cancer Immunol Immunother. 63:67–72. 2014. View Article : Google Scholar : PubMed/NCBI
18	Mund C, Brueckner B and Lyko F: Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: Basic concepts and clinical applications. Epigenetics. 1:7–13. 2006. View Article : Google Scholar : PubMed/NCBI
19	Raj K, John A, Ho A, Chronis C, Khan S, Samuel J, Pomplun S, Thomas NS and Mufti GJ: CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia. 21:1937–1944. 2007. View Article : Google Scholar : PubMed/NCBI
20	Pinto A, Attadia V, Fusco A, Ferrara F, Spada OA and Di Fiore PP: 5-Aza-2-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood. 64:922–929. 1984. View Article : Google Scholar : PubMed/NCBI
21	Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V, Luna R, Rashid A, Shen L, Estecio MR, et al: DNA methylation changes after 5-aza-2-deoxycytidine therapy in patients with leukemia. Cancer Res. 66:5495–5503. 2006. View Article : Google Scholar : PubMed/NCBI
22	Kim HP and Leonard WJ: CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: A role for DNA methylation. J Exp Med. 204:1543–1551. 2007. View Article : Google Scholar : PubMed/NCBI
23	Wilson CB, Rowell E and Sekimata M: Epigenetic control of T-helper-cell differentiation. Nat Rev Immunol. 9:91–105. 2009. View Article : Google Scholar : PubMed/NCBI